Alphamab Oncology Announces First Patient Dosed in the Pivotal Clinical Study of KN046 for the Treatment of PD-(L)1 Refractory Advanced NSCLC
SUZHOU, China, Oct. 29, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced, a pivotal clinical study of PD-L1/CTLA-4 bispecific antibody KN046 in China (ENREACH-LUNG-02) recently completed the first drug administration. ENREACH-LUNG-02 is a multi-center, open-label, randomized-controlled phase II/III clinical study. Phase III study is planned to be carried out in about 50 research centers, recruiting about 486 patients, with...
Hanmi Science Consortium Drives Ambitious Project for Worldwide Vaccine Equity
SEOUL, South Korea, Oct. 29, 2021 /PRNewswire/ -- Hanmi Science doesn't just want the world to know they are committed to vaccine equity, they want to prove it. Mr. Lim, CEO of Hanmi Science, echoes the concerns of Mr. Bill Gates, co-founder of the Bill & Melinda Gates Foundation. As Mr. Gates stated in an April 25 Sky News...
Exosystems Raises $3.9M Series A Funding, on Mission to Provide AI-based Digital Care for Musculoskeletal System
SEOUL, South Korea, Oct. 29, 2021 /PRNewswire/ -- Exosystems, an artificial intelligence (AI)-based digital healthcare company and a member of Born2Global Centre, has succeeded in attracting Series A funding worth USD 3.9 million from SBI Investment, Laguna Investment, and Korea Technology Finance Corporation. With the addition of the new investments, the company has now amassed a total of USD...
111 to Announce Third Quarter 2021 Unaudited Financial Results on November 19, 2021 – Conference Call to Follow
SHANGHAI, Oct. 29, 2021 /PRNewswire/ – 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2021, before the U.S. market opens on Friday, November...
World Stroke Day: Global survey reveals only 35% hospitals worldwide provide essential stroke treatment
GENEVA, Oct. 29, 2021 /PRNewswire/ -- On World Stroke Day, 29 October, the World Stroke Organization (WSO) is calling for urgent action after a survey by the WSO and the World Health Organization (WHO) found that only 35% of hospitals worldwide provide essential clot-busting medicine tissue plasminogen activator (tPA), despite it being added...
Uniting for Action Against Psoriatic Disease
World Psoriasis Day STOCKHOLM, Oct. 29, 2021 /PRNewswire/ -- Psoriatic disease is a disfiguring and disabling condition with no known cure. Visible skin plaques and inflamed joints are characteristic physical symptoms, but people living with psoriatic disease also face many emotional, social, and economic hardships. It is time to put an end to...
ImmunoForge Inc. receives U.S. FDA ODD for PF1801
SEOUL, South Korea and SILVER SPRING, Md., Oct. 29, 2021 /PRNewswire/ -- ImmunoForge (Co-CEOs Sung-Min Ahn, Kiho Chang), a company specializing in developing new drugs for rare musculoskeletal diseases, has reported that their new drug candidate PF1801 which is in development for treatment of Duchenne Muscular Dystrophy(DMD) and Polymyositis (PM) has received...
Yili Becomes the Largest Shareholder of Ausnutria, Accelerating its Development of Goat Milk Formula and Nutrition Products
BEIJING, Oct. 28, 2021 /PRNewswire/ -- On October 27, Inner Mongolia Yili Industrial Group Co., Ltd. ("Yili Group" or "Yili"), the largest dairy producer in Asia, announced that it took a stake in goat milk formula giant Ausnutria Dairy Co. Ltd. ("Ausnutria Dairy" or "Ausnutria") and became its largest shareholder. This marked the largest M&A deal for China's dairy...
HanAll Biopharma Reports Third Quarter 2021 Results
Q3'21 sales of KRW 25.5 billion increased 15% from the same period last year Q3'21 operating profit of KRW 2.2 billion grew by 120% compared to Q3'20 Nine months sales of KRW 76.7 billion and operating profit of KRW 9.2 billion rose by 15% and 67% YoY, repectively ...
Jubilee Biotech has developed JUBIwatch, “Health and Life are now wearable”
SEOUL, South Korea, Oct. 28, 2021 /PRNewswire/ -- Jubilee Biotech, a startup in South Korea, has developed JUBIwatch, a smart watch and medication management platform that uses microneedles to administer exact amounts of medication at set times. "Wearing, setting up, and sending information on medication." This is the phrase that has inspired the slogan "wear, set, and forget," which...
